Dr. MartensLSE:DOCS +1.30%52 EBITDA Margin % is 20.14% as of Mar. 2026, which is 9% above its 10-year median of 18.54. GuruFocus rates LSE:DOCS with a GF Score™ of 52/100 and a GF Value™ of £0.72 (Fairly Valued). The stock has 3 warning signs investors should review. Among 1,043 Manufacturing - Apparel & Accessories companies, Dr. Martens ranks better than 79.87% on this metric.
EBITDA Margin % is calculated as EBITDA divided by its Revenue. Dr. Martens's EBITDA for the
six
months ended in Mar. 2026 was £89.2 Mil. Dr. Martens's Revenue for the
six
months ended in Mar. 2026 was £442.9 Mil. Therefore, Dr. Martens's EBITDA margin for the quarter that ended in Mar. 2026 was 20.14%.
Dr. Martens (LSE:DOCS) EBITDA Margin % Explanation
EBITDA Margin % is the ratio of EBITDA divided by net sales or Revenue. It is an performance metric measuring company's operating profitability. EBITDA Margin takes depreciation and amortization, interest expense and tax into account, which makes it easy to compare the relative profitability of companies of different sizes in the same industry.
Dr. Martens EBITDA Margin % Related Terms
Dr. Martens EBITDA Margin % Historical Data
* Premium members only.
The historical data trend for Dr. Martens's EBITDA Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
LSE:DOCS vs NKE, DECK, ONON: EBITDA Margin % Comparison
For the Footwear & Accessories subindustry, Dr. Martens's EBITDA Margin %, along with its competitors' market caps and EBITDA Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Dr. Martens EBITDA Margin % vs Manufacturing - Apparel & Accessories Industry
For the Manufacturing - Apparel & Accessories industry and Consumer Cyclical sector, Dr. Martens's EBITDA Margin % distribution charts can be found below:
* The bar in red indicates where Dr. Martens's EBITDA Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Dr. Martens (LSE:DOCS) has a EBITDA Margin % of 20.14% as of Mar. 2026. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on Dr. Martens and its competitors. This is near median its historical median of 18.54. Over the past decade, Dr. Martens' EBITDA Margin % has ranged from 13.20 to 29.19. According to the industry distribution chart, Dr. Martens ranks #210 out of 1043 companies in the Manufacturing - Apparel & Accessories industry, placing it in the top 20.1%.
Is Dr. Martens' EBITDA Margin % too high?
Dr. Martens' current EBITDA Margin % of 20.14% is near median its 10-year median of 18.54. Over the past 10 years, this metric has ranged from a low of 13.20 to a high of 29.19. The Manufacturing - Apparel & Accessories industry median EBITDA Margin % is 8.37. Dr. Martens' value of 20.14% is 140.6% above this industry median. Based on the distribution chart, Dr. Martens ranks #210 out of 1043 companies in the Manufacturing - Apparel & Accessories industry, which is in the top quartile — a strong position relative to peers. Overall, Dr. Martens has a GF Score™ of 52/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Dr. Martens' EBITDA Margin % compare to NKE and DECK?
According to the Manufacturing - Apparel & Accessories industry distribution chart, Dr. Martens ranks #210 out of 1043 companies for EBITDA Margin %. This places Dr. Martens in the top 20% of its industry — outperforming the majority of peers. The industry median EBITDA Margin % is 8.37. Dr. Martens' value of 20.14% is 140.6% above this benchmark. Historically, Dr. Martens' own EBITDA Margin % has ranged from 13.20 to 29.19 over the past decade. While the company's 10-year median is 18.54 vs. the industry median of 8.37, Dr. Martens has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBITDA Margin % for a Manufacturing - Apparel & Accessories company?
The median EBITDA Margin % among Manufacturing - Apparel & Accessories companies is 8.37, based on 1,043 companies in the industry. Companies in the top quartile (top 25%) have a EBITDA Margin % significantly above this median, while those in the bottom quartile fall well below. However, EBITDA Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Dr. Martens's current EBITDA Margin % of 20.14% is 140.6% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBITDA Margin % mean?
A high EBITDA Margin % can signal that a stock is expensive relative to its fundamentals. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on Dr. Martens and its competitors. For the Manufacturing - Apparel & Accessories industry, the median EBITDA Margin % is 8.37 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Dr. Martens's current EBITDA Margin % is 20.14%, which is near median its own 10-year median of 18.54. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Dr. Martens stock overvalued right now?
Based on GuruFocus' analysis, Dr. Martens (LSE:DOCS) is currently considered Fairly Valued. The stock's GF Value™ is £0.72, compared to a current price of £0.70 — trading 2.5% below its estimated fair value. The current EBITDA Margin % is 20.14%, which is near median its 10-year median of 18.54 and 140.6% above the Manufacturing - Apparel & Accessories industry median of 8.37. Dr. Martens' overall GF Score™ is 52/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBITDA Margin % calculated?
EBITDA Margin % is calculated from a company's financial statements. For Dr. Martens (LSE:DOCS), the current EBITDA Margin % is 20.14% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Dr. Martens (LSE:DOCS) Overvalued in 2026?
Based on GuruFocus' analysis, Dr. Martens stock appears to be undervalued.
The current stock price of £0.70 is trading 2.5% below its estimated GF Value™ of £0.72.
GuruFocus considers Dr. Martens to be Fairly Valued.
Key valuation signals for LSE:DOCS:
EBITDA Margin %: 20.14% (near median its 10-year median of 18.54)
GF Value™: £0.72 vs. price of £0.70 (2.5% below fair value)
Industry Position: 140.6% above the Manufacturing - Apparel & Accessories median (#210 of 1043)
No single metric tells the full story. See the LSE:DOCS stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Dr. Martens PLC is engaged in the footwear business. Its product segments include Originals, Fusion, Kids and Casual, and a complementary range of Accessories. The company has sales through E-commerce, Retail, and Wholesale of Products. Geographically, it derives the majority of its revenue from EMEA and has a presence in the Americas and APAC.
52GF Score
Get the complete analysis for LSE:DOCS
EBITDA Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
LSE:DOCS has been successfully added to your 
